Natera’s Signatera gains European IVDR certification across multiple cancers, opening a new phase for personalized MRD testing and clinical adoption.
Multikine still awaits a commercial breakthrough. CEL-SCI’s Saudi deal tests whether regional oncology access can change that trajectory.
Find out how Juniper Biosciences is using FMISO imaging to personalize radiation therapy and reduce toxicity in head and neck cancer.
TAE Life Sciences’ BNCT study showed stronger boron delivery and immune effects in preclinical models. Read what this could change for oncology.
Rakuten Medical taps LOTTE Biologics for global supply of its Alluminox cancer platform. Find out what this deal means for photoimmunotherapy’s future.
See how Naveris’s NavDx ctHPV DNA results are reshaping HPV cancer surveillance and what this means for clinicians, payers, and precision oncology adoption.
Kallisio has begun clinical implementation of its FDA-cleared Stentra system at Stanford Health Care, marking the first reported integration of the patient-specific intraoral device into a major U.S. hospital’s workflow for head and neck cancer radiation therapy. The system, which received 510(k) clearance in January 2024, enables individualized immobilization of oral structures during intensity-modulated radiation
BioAtla and GATC Health advance Ozuriftamab Vedotin into a Phase 3 trial for OPSCC via SPV financing. Discover how this targets cancer and aging together.
Privo Technologies has officially initiated dosing in a Phase 1/2 trial evaluating PRV131, its nanoengineered intratumoral cisplatin injectable, for the treatment of T1–T3 oral squamous cell carcinoma (OSCC). The trial, designated Arm 3 of the CLN-004 study, will explore PRV131 as a neoadjuvant therapy aimed at shrinking tumors before surgery. The announcement marks a pivotal
A new phase III clinical trial published in The Lancet has shown that proton therapy significantly improves overall survival and reduces treatment-related toxicities in patients with oropharyngeal cancers compared to traditional photon-based radiation. Conducted across 21 U.S. institutions and led by researchers at the University of Texas MD Anderson Cancer Center, the study is the